Pipamperone (Dipiperon) in the treatment of behaviour disorders. A large-scale multicentre evaluation.
Pipamperone solution or tablets were prescribed for four weeks to 188 patients (3-100 years) with behavior disorders. Fifty of these (group A) were mental retardates, the remaining 138 (group B) had a normal I.Q. Their doses were gradually increased until optimal effect was reached. Nearly all 17 items of a behaviour rating scale had improved very significantly by the end of the fourth week, while in 82% of the patients of group A and 76% of group B results were rated good to very good. Also, pipamperone proved to be far superior to previous psychotropic drugs in patients who had been treated before.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000437:Alcoholism / Q000150:complications; D002090:Butyrophenones / Q000627:therapeutic use*; D055598:Chemical Phenomena; D002621:Chemistry; D002648:Child; D002653:Child Behavior Disorders / Q000188:drug therapy*; D002675:Child, Preschool; D004341:Drug Evaluation; D004827:Epilepsy / Q000150:complications; D005260:Female; D006801:Humans; D008607:Intellectual Disability / Q000150:complications; D007540:Isonipecotic Acids / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011618:Psychotic Disorders / Q000150:complications; D012920:Social Behavior Disorders / Q000188:drug therapy*; D014149:Tranquilizing Agents / Q000627:therapeutic use*
D002090:Butyrophenones; D007540:Isonipecotic Acids; D014149:Tranquilizing Agents; C005569:pipamperone